JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type I… Read more
JCR Pharmaceuticals Co., Ltd. (JCR) - Net Assets
Latest net assets as of September 2025: €48.52 Billion EUR
Based on the latest financial reports, JCR Pharmaceuticals Co., Ltd. (JCR) has net assets worth €48.52 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€109.06 Billion) and total liabilities (€60.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €48.52 Billion |
| % of Total Assets | 44.49% |
| Annual Growth Rate | -2.44% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.2 |
JCR Pharmaceuticals Co., Ltd. - Net Assets Trend (2022–2025)
This chart illustrates how JCR Pharmaceuticals Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for JCR Pharmaceuticals Co., Ltd. (2022–2025)
The table below shows the annual net assets of JCR Pharmaceuticals Co., Ltd. from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €47.44 Billion | -16.01% |
| 2024-03-31 | €56.48 Billion | +7.75% |
| 2023-03-31 | €52.41 Billion | +2.59% |
| 2022-03-31 | €51.09 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to JCR Pharmaceuticals Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €31.19 Billion | 66.31% |
| Other Components | €15.85 Billion | 33.69% |
| Total Equity | €47.04 Billion | 100.00% |
JCR Pharmaceuticals Co., Ltd. Competitors by Market Cap
The table below lists competitors of JCR Pharmaceuticals Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
$237.63 Million |
|
Ningbo Gaofa Automotive Ctrl
SHG:603788
|
$237.64 Million |
|
SONIDA SENIOR LIV. DL-01
F:13C0
|
$237.68 Million |
|
Nanjing Chervon Auto Precision Technology Co Ltd
SHG:603982
|
$237.73 Million |
|
Andes Technology Corp
TW:6533
|
$237.45 Million |
|
Bairong Inc.
PINK:BAIGF
|
$237.44 Million |
|
Investar Holding Corp
NASDAQ:ISTR
|
$237.39 Million |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
$237.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JCR Pharmaceuticals Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 56,176,000,000 to 47,040,000,000, a change of -9,136,000,000 (-16.3%).
- Net loss of 4,759,000,000 reduced equity.
- Dividend payments of 2,505,000,000 reduced retained earnings.
- Other factors decreased equity by 1,872,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.76 Billion | -10.12% |
| Dividends Paid | €2.50 Billion | -5.33% |
| Other Changes | €-1.87 Billion | -3.98% |
| Total Change | €- | -16.26% |
Book Value vs Market Value Analysis
This analysis compares JCR Pharmaceuticals Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €411.14 | €3.22 | x |
| 2023-03-31 | €418.04 | €3.22 | x |
| 2024-03-31 | €450.11 | €3.22 | x |
| 2025-03-31 | €386.09 | €3.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JCR Pharmaceuticals Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.39%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 2.23x
- Recent ROE (-10.12%) is below the historical average (8.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 28.51% | 28.40% | 0.53x | 1.91x | €9.42 Billion |
| 2023 | 7.23% | 10.98% | 0.36x | 1.82x | €-1.44 Billion |
| 2024 | 9.80% | 12.85% | 0.42x | 1.82x | €-110.60 Million |
| 2025 | -10.12% | -14.39% | 0.32x | 2.23x | €-9.46 Billion |
Industry Comparison
This section compares JCR Pharmaceuticals Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $638,205,725,333
- Average return on equity (ROE) among peers: -14.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JCR Pharmaceuticals Co., Ltd. (JCR) | €48.52 Billion | 28.51% | 1.25x | $237.56 Million |
| Bayer Aktiengesellschaft (BAYA) | $30.70 Billion | -34.19% | 2.81x | $10.29 Billion |
| EH3 (EH3) | $486.18 Million | -16.90% | 0.41x | $245.45 Million |
| Otsuka Holdings Co. Ltd (OS1) | $1.88 Trillion | 7.87% | 0.40x | $26.35 Billion |